Neuralstem Cell Therapy

for Chronic Motor Disorders from Stroke

• Product status:
  • U.S.: Advanced preclinical program with the University of Pittsburgh
  • China: Trial expected to commence in the second half of 2012, in collaboration with BaYi Brain Hospital in Beijing
• Mechanism of Action: Rebuilding neural circuitry lost to ischemic damage and production of factors that promote repair and recovery of surviving tissue
• Route of Administration: Direct stereotactic injections into the brain

In preclinical work, Neuralstem’s human spinal cord stem cells (HSSCs) survived in rat brains affected by stroke and differentiated predominantly into neurons. After four weeks, the transplanted rats showed significant improvement in some motor skill and strength measurements, including significantly decreased asymmetric body swing; increased vertical movements; and increased grip strength -- all measures of stroke-induced motor impairment.

In humans, Neuralstem will be targeting the neural circuitry that controls motor function. The proposed method of delivery will be transplantation near the motor tracts close to the stroke lesion in the brain in order to promote regeneration and repair.

Neuralstem’s Stroke Clinical Program

Neuralstem plans to pursue clinical programs in motor disorders from stroke in the U.S., and in China through its wholly owned subsidiary, Neuralstem China.

The company is collaborating with the University of Pittsburgh in an advanced preclinical stroke program. Neuralstem China is working with BaYi Brain Hospital in Beijing. The China stroke trial is expected to commence in the second half of 2012.

Patient Resources:

For more information on stroke:

• National Stroke Association http://www.stroke.org/site/PageNavigator/HOME